Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Cited by (743)

Items 501–600 of 743

1. Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer
   Maibritt Nørgaard, Maria Rusan, Karoline Kondrup, Ea Marie Givskov Sørensen, Simone Weiss, Marianne Trier Bjerre, Jacob Fredsøe, Søren Vang, Jørgen Bjerggaard Jensen, Bram De Laere et al. · 2025 · Journal of Experimental & Clinical Cancer Research
2. A Cyanobacteria-Derived RNA Aptamer Resensitizes Prostate Cancer to Hormone Therapy
   Carlos D. Cruz-Hernández, Bethany Smith, Sandrine Billet, Manish Thiruvalluvan, Gabrielle Gonzales, David M. Underhill, Ekihiro Seki, Shelly Chi-Loo Lu, Neil A. Bhowmick · 2025 · Cancer Research
3. JAK inhibition shows two faces in prostate cancer
   Nicholas J. Brady, Christopher E. Barbieri · 2022 · Nature Cancer
4. Expression of high molecular weight cytokeratin—A novel feature of aggressive and innate hormone‐refractory prostatic adenocarcinoma
   Jiajie G. Lu, Emily T. Lo, Cleandrea Williams, Brian Ma, Andy E. Sherrod, Guang‐Qian Xiao · 2022 · The Prostate
5. Single-cell analysis of castration-resistant prostate cancers to identify potential biomarkers for diagnosis and prognosis of neuroendocrine prostate cancer.
   Yung-Chih Hong, Tze-Yun Hu, Chi‐Hsin Hsu, Wayne Wei Yeh, W. J. Wong, Tsai-Wen Shen, Ching-Hsin Chang, Kate Hua, Chien-Yi Tung, Yu‐Ching Peng et al. · 2023 · PubMed Central
6. Tumor-associated antigen targets for novel immune-based strategies in prostate cancer
   Amman Bhasin, Patrick Johnston Mille, Aditya Eturi, Andrew John Iskander, William J. Tester, Kevin Kayvan Zarrabi · 2024 · Journal of Translational Genetics and Genomics
7. Exploring B7-H4’s Role in Prostate Cancer Dormancy after Androgen Deprivation Therapy: Extracellular Matrix Interactions and Therapeutic Opportunities
   Ning Kang, Hui Xue, Nelson K.Y. Wong, Yen‐Yi Lin, Adam Classen, Rebecca Wu, Htoo Zarni Oo, Xin Dong, Angela M. Trinh, Dong Lin et al. · 2025 · Molecular Cancer Research
8. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer
   Atish Dipankar Choudhury, Kathryn P. Gray, Jeffrey G. Supko, Lauren C. Harshman, Mary‐Ellen Taplin, Amanda Fredericks Pace, Matthew S. Farina, Katherine Zukotynski, Brandon David Bernard, Philip W. Kantoff et al. · 2018 · The Prostate
9. Therapy-induced small-cell disease: from mouse to man and back
   Magdalena M. Grabowska, Robert J. Matusik · 2018 · Nature Reviews Urology
10. FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
    Leandro H. Gallo · 2021 · Oncotarget
11. Influence of Androgen Receptor Antagonist MDV3100 Therapy on Rats With Benign Prostatic Hyperplasia
    Minggen Yang, Zhenqiang Xu, Zhiming Zhuang · 2021 · International Neurourology Journal
12. Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide
    Takashi Matsuoka, Aiko Sugiyama, Yoshifumi Miyawaki, Yusuke Hidaka, Yukiko Okuno, Hiroaki Sakai, Hiroki Tanaka, Kiyotsugu Yoshikawa, Tomohiro Fukui, Kei Mizuno et al. · 2023 · Cancer Science
13. A network-based integration for understanding racial disparity in prostate cancer
    Baoyi Zhang, Kevin Yao, Chao Cheng · 2022 · Translational Oncology
14. Neural Transcription Factors in Disease Progression
    Daksh Thaper, Sepideh Vahid, Amina Zoubeidi · 2019 · Advances in experimental medicine and biology
15. Evolution of the prostate cancer genome towards resistance
    Francesca Lorenzin, Francesca Demichelis · 2019 · Journal of Translational Genetics and Genomics
16. Novel approaches targeting mitochondrial fission to deplete stem-like tumor cells in prostate cancer and improve treatment outcomes
    Antonino Passaniti, Arif Hussain · 2019 · Annals of Translational Medicine
17. Schlafen family member 5 (SLFN5) regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer
    Rafael S. Martinez, Mark J. Salji, Linda K. Rushworth, Chara Ntala, Giovanny Rodriguez Blanco, Ann Hedley, William Andrew Clark, Paul Peixoto, Éric Hervouet, Elodie Renaude et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
18. Reversal of lineage plasticity in RB1/TP53-deleted prostate cancer through FGFR and Janus kinase inhibition
    Wouter R. Karthaus, Joseph Minhow Chan, Manu N. Setty, Jillian R Love, Samir Zaidi, Zi-Ning Choo, Sitara Persad, Justin R. LaClair, Kayla E. Lawrence, Ojasvi Chaudhary et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
19. Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer
    Shan Li, Kai Song, Huiyun Sun, Yong Tao, Arthur J. Y. Huang, Vipul Bhatia, Brian P. Hanratty, Radhika A. Patel, Henry W. Long, Colm M. Morrissey et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
20. Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance
    Shuai Gao, Nolan D. Patten, Changmeng Cai · 2025 · Journal of the National Cancer Center
21. Global burden, trends, and projections to 2050 of neuroblastoma and other peripheral nervous cell tumors: a systematic analysis of the global burden of disease study from 1990 to 2021
    Hang Wu, Jingjing Li, Yue Yang, Xiaoqi Xuan, Jin‐Long Yang · 2025 · Frontiers in Pediatrics
22. Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy
    Manon Baurès, Anne-Sophie Vieira Aleixo, Emeline Pacreau, Aysis Koshy, Vanessa Cristina Ribeiro Friedrich, Marc Diedisheim, Martin Raigel, Yichao Hua, Charles Dariane, Florence Boutillon et al. · 2026 · EMBO Molecular Medicine
23. Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives
    Emilio Francesco Giunta, Giuseppe Schepisi, Sara Bleve, Riccardo Serra, Nicole Brighi, Irene Torresan, Elisa Tassinari, Sofia Zanuccoli, Cristian Lolli · 2026 · Discover Oncology
24. Deciphering double-negative prostate cancer: from aggressive subtype to novel therapeutic paradigms
    Jie Wang, Ruicheng Wu, Zhouting Tuo, Uzoamaka Adaobi Okoli, Zhipeng Wang, Premkamon Chaipanichkul, Siang‐Boon Koh, Dengxiong Li, Zhaojie Lyu, Umber Cheema et al. · 2026 · Cell Communication and Signaling
25. Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities
    Nick R. Waldron, Diogo Da Silva, Daniel Westaby, Juan M. Jiménez‐Vacas, Joe Taylor, Adam Sharp · 2026 · British Journal of Cancer
26. Single-cell and spatial RNA sequencing in prostate cancer
    Amin Ali, Migle Mikutenaite, Joachim Weischenfeldt, Robert Glen Bristow · 2026 · Nature Reviews Urology
27. Development of diabetes mellitus following hormone therapy in prostate cancer patients is associated with early progression to castration resistance
    Tomonori Hayashi, Tomoyoshi Miyamoto, Noriaki Nagai, Atsufumi Kawabata · 2021 · Scientific Reports
28. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer
    Daniel J. Turnham, Manisha S. Mullen, Nicholas Bullock, Kathryn L. Gilroy, A. Richards, Radhika A. Patel, Marcos Quintela, Valérie S. Méniel, Gillian Seaton, Howard Kynaston et al. · 2024 · Cells
29. Androgens and androgen receptor directly induce the thickening, folding, and vascularization of the seahorse abdominal dermal layer into a placenta-like structure responsible for male pregnancy via multiple signaling pathways
    Yichao Zhang, Xue‐Hui Shi, Meilun Shi, Jun Li, Qinghua Liu · 2024 · International Journal of Biological Macromolecules
30. Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven Seven-Gene Stemness Signature That Predicts Progression
    Agustina Ayelen Sabater, Pablo Sanchis, Rocio A. Seniuk, Gastón Pascual, Nicolás Anselmino, Daniel F. Alonso, Federico Cayol, Elba Susana Vazquez, Marcelo Adrian Marti, Javier Cotignola et al. · 2024 · International Journal of Molecular Sciences
31. PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide
    TOSHIKI OKA, Koji Hatano, Masaru Tani, Akihiro Yoshimura, Yuki Horibe, Yutong Liu, Nesrine Sassi, Yohei Okuda, AKINARU YAMAMOTO, Toshihiro Uemura et al. · 2024 · Cancer Diagnosis & Prognosis
32. Ubiquitin C-terminal hydrolase L1 is a regulator of tumor growth and metastasis in double-negative prostate cancer
    Shiqin Liu · 2024 · American Journal of Clinical and Experimental Urology
33. Targeting Aggressive Prostate Carcinoma Cells with Mesothelin-CAR-T Cells
    Apolline de Testas de Folmont, Angèle Fauvel, Francis Vacherot, Pascale Soyeux, Abdérémane Abdou, Salem Chouaı̈b, Stéphane Terry · 2025 · Biomedicines
34. The role of SOX transcription factors in prostate cancer: Focusing on SOX2
    Guotu Du, Xiang Huang, Peng Su, Ying Yang, Shicheng Chen, Tianyu Huang, Neng Zhang · 2025 · Genes & Diseases
35. Performance Evaluation of the KRYPTOR Compact PLUS Analyzer-Based B.R.A.H.M.S. CgA Ⅱ KRYPTOR Assay for Chromogranin A Measurement
    Yu Jeong Choi, Juhye Roh, Sinyoung Kim, Kyung‐A Lee, Younhee Park · 2021 · Diagnostics
36. Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey−Holden prostate cancer academy meeting
    Andrea K. Miyahira, Jessica E. Hawley, Remi M. Adelaiye-Ogala, Jérémie Calais, Lucia Nappi, Ravi Bharat Parikh, Tyler M. Seibert, Elizabeth V. Wasmuth, Xiao X. Wei, Kenneth J. Pienta et al. · 2022 · The Prostate
37. Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer
    Yongkang Ye, Rujun Mo, Ruinian Zheng, Jun Zou, Shaoqian Liu, Qiwu Mi, Weide Zhong · 2023 · Disease Markers
38. Prostate Cancer: Advances in Genetic Testing and Clinical Implications
    Ahmad Abdelrazek, Khaled Ghoniem, Mohamed ElMakki Ahmed, Vidhu B. Joshi, Ahmed M. Mahmoud, Nader Saeed, Nazih P. Khater, Mohammed Said ElSharkawy, Ahmed Gamal, Eugene D. Kwon et al. · 2023 · Uro
39. An unbiased seed-based RNAi selection screen identifies small RNAs that inhibit androgen signaling and prostate cancer cell growth
    Joshua M. Corbin, Constantin Georgescu, Lin Wang, Jonathan D. Wren, Magdalena Bieniasz, Chao Xu, Adam Steven Asch, María Jesús Ruiz-Echevarría · 2023 · Molecular Therapy — Nucleic Acids
40. CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer
    Romie Angelo G Azur, Kevin Christian V. Olarte, Weand S. Ybañez, Alessandria Maeve M. Ocampo, Pia Bagamasbad · 2024 · PLoS ONE
41. CDHu40: a novel marker gene set of neuroendocrine prostate cancer
    Sheng Liu, Hye Seung Nam, Ziyu Zeng, Xuehong Deng, Elnaz Pashaei, Yong Zang, Lei Yang, Chenglong Li, Jiaoti Huang, Michael K. Wendt et al. · 2024 · Briefings in Bioinformatics
42. Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC)
    Ajit Kumar Navin, Chalikkaran Thilakan Rejani, Balaji Chandrasekaran, Ashish Tyagi · 2025 · Biomedicine & Pharmacotherapy
43. BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature–positive castration-resistant prostate cancer
    Shipra Shukla, Dan Li, Woo Hyun Cho, Dana M. Schoeps, Holly M. Nguyen, Jennifer L. Conner, Marjorie L. Roskes, Anisha B. Tehim, Gabriella Bayshtok, Mohini R. Pachai et al. · 2025 · Journal of Clinical Investigation
44. Identification of protein kinase C beta as a therapeutic target for neuroendocrine prostate cancer and development of a nanoparticle-based therapeutic strategy
    Yunkai Qie, Zhaoxia Cheng, Zhouliang Wu, Feilong Qi, Bozhao Li, Suying Wu, Tianjiao Chu, Zefang Lu, Suping Li, Guangjun Nie · 2022 · Nano Today
45. Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU‐AA‐302
    Benjamin A. Teply, Fang Qiu, Emmanuel S. Antonarakis, Michael Anthony Carducci, Samuel Ray Denmeade · 2019 · The Prostate
46. [Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].
    Yi-Hong Ou, Yaodong Jiang, Qi Li, Yong-Jiang Zhuang, Qiang Dang, Wanlong Tan · 2018 · Europe PMC (PubMed Central)
47. Towards understanding androgen receptor-independent prostate cancer: an evolving paradigm
    Jianfu Zhou, Yuliang Wang, Songtao Xiang, Franky Leung Chan · 2020 · Translational Cancer Research
48. The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer
    Michael L. Beshiri, Brian J. Capaldo, Ross G. Lake, Anson T. Ku, Danielle N. Burner, Caitlin M. Tice, Crystal Tran, Julianna Kostas, Aian Neil Alilin, JuanJuan Yin et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
49. HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complex
    Shreyas Lingadahalli, Betul Ersoy-Fazlioglu, Umut Berkay Altıntaş, Ahmet Cingöz, Emirhan Tekoglu, Ivan Pak Lok Yu, Ugur Meric Dikbas, Hans Andomat, İbrahim Kulaç, Tunç Morova et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
50. Prostate Cancer: Insights into Disease Progression and Therapeutic Challenges
    Debanjan Chakroborty, Ajay P. Singh · 2024 · International Journal of Molecular Sciences
51. A single-cell and spatial atlas of prostate cancer reveals the combinatorial nature of gene modules underlying lineage plasticity and metastasis
    Hanbing Song, Junxiang Xu, Keila Velázquez-Arcelay, Arda Demirci, Brendan Lapointe Raizenne, Sarah C. Hsu, Joshua Choi, Julia H. Pham, Yih-An Chen, Hannah N. W. Weinstein et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
52. Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer
    Daniel Jia Ming Ang, Johan Chan, Whee Sze Ong, Hui Shan Tan, Quan Sing Ng, John Shyi Peng Yuen, Kenneth Chen, Kae Jack Tay, Siew Wei Wong, Marniza Bte Saad et al. · 2024 · JCO Precision Oncology
53. Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer
    Aiden Deacon, Ava P. Gustafson, Allison Makovec, Ella Boytim, Gabriella von Dohlen, David R. Moline, Elin Kairies, Sam Kellen, Khalid Ishani, Megan Ludwig et al. · 2025 · Oncotarget
54. Autocrine Fibroblast Growth Factor Receptor 1 Signaling Activates Lactate Dehydrogenase A-Aerobic Glycolysis for Advanced Human Prostate Tumor Growth
    Xiaoming Xu, Li Wang, Hua-Feng Pan, T. Gu, Zhong-Liang Cheng, Tianjun Peng, Jianting Zhang, Jiaren Pan · 2025 · Prostate Cancer
55. Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer
    Pengfei Xu, Huan Qu, Joy C. Yang, Wei Fan, Junwei Zhao, Menghuan Tang, Leyi Wang, Christopher Nip, Henson Li, Allen C. Gao et al. · 2025 · Cancers
56. Elimination of docetaxel-induced senescence attenuates malignant progression in RB1-deficient CRPC
    Huilan Su, Liqun Huang, Wenwen Xia, Dean G. Tang, Jianjun Zhou, Guosheng Yang · 2025 · Cellular Oncology
57. PEAK1 promotes prostate cancer progression and docetaxel resistance by mediating the polarization of tumor-associated macrophages
    Jianxin Ni, Xuelian Li, Zhengqi Shi, Boxin Guo, Yongfei Duan, Yongpan An, Ruixiao Li · 2026 · European journal of medical research
58. Targeting GRP78 and the Proteostasis Network to Break the Therapeutic Ceiling in Neuroendocrine Prostate Cancer
    Amos Olalekan Akinyemi, Md Rakibul Alam, Mithu Howlader, Mohammad Esfini Farahani, Lixiang Gu, Chun Li, Chripus Ngule, Kevin L. Fulp, Bolaji C. Dayo Owoyemi, Xinyi Wang et al. · 2026 · iNew Medicine
59. Multi-omics evaluation of cell lines as models for metastatic prostate cancer
    Xueying Liu, Weixing Yu, Xiuyuan Jin, Yugang Wang, Ke Liu · 2026 · Communications Biology
60. Therapeutic targeting of the eIF4E cap-binding domain reveals control of lineage fate in prostate cancer
    Rashmi Mishra, Sihyeon Song, Dhruv Choradia, Dmytro Rudoy, Cynthia L. Wladyka, Patrick Hoang, Jin Yeong kim, Ilsa M. Coleman, Sonali Arora, Stephanie Dobersch et al. · 2026 · Journal of Clinical Investigation
61. Game of clones: decipher lineage plasticity in hormone-driven cancers
    Amanda Leonita, Siyuan Cheng, Joshua Warrick, Isaac Yi Kim, Su Deng, Ping Mu · 2026 · Cellular and Molecular Life Sciences
62. Case Series of Men with the Germline APC I1307K variant and Treatment-Emergent Neuroendocrine Prostate Cancer
    Minas Platon Economides, Mari Nakazawa, Jonathan W. Lee, Xiaochun Li, Lucas Hollifield, Rachelle Chambers, Michal Sarfaty, Judith D. Goldberg, Emmanuel S. Antonarakis, David R. Wise · 2023 · Clinical Genitourinary Cancer
63. Novel Insights on the Role of Epigenetics in Androgen Receptor’s Expression in Prostate Cancer
    Vânia Camilo, Mariana Brütt Pacheco, Filipa Moreira‐Silva, Gonçalo Outeiro-Pinho, Vítor M. Gaspar, João Filipe Mano, Cristina Joana Marques, Rui Henrique, Cármen Jerónimo · 2023 · Biomolecules
64. Impact of cell plasticity on prostate tumor heterogeneity and therapeutic response
    Maddison Archer · 2024 · American Journal of Clinical and Experimental Urology
65. LKB1 inactivation unleashes prostate cancer lineage plasticity
    Shaghayegh Nouruzi, Amina Zoubeidi · 2025 · Cell Research
66. Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to Docetaxel
    Alfonso Manuel Durán, Kristen Whitley, Krystal Santiago, Christian H. Yoo, Giancarlo Valdez, Kai Wen Cheng, Pedro T. Ochoa, David de Semir, Joanne Xiu, Parthiban Chokkalingam et al. · 2025 · Cancers
67. Comprehensive single-cell transcriptomic analysis reveals fibroblast subpopulations and the prognostic association of COMT in prostate cancer progression全面的单细胞转录组分析揭示了成纤维细胞亚群，并探讨了 COMT 在前列腺癌进展中的预后关联全面的单细胞转录组分析揭示了成纤维细胞亚群，并探讨了 COMT 在前列腺癌进展中的预后关联
    Weimin Shan, Bo Guan, Weiwei Ma, Runzhe Fan, Di Cui, Zongyao Hao · 2025 · Scientific Reports
68. Protein translation controlled by the androgen receptor in prostate cancer: a novel therapeutic option?
    Kimia Mirzakhani, Aria Baniahmad · 2020 · Translational Cancer Research
69. Effects of medicinal plants and natural compounds in models of prostate cancer related to sex steroids: A systematic review
    Rafael Abe da Rocha Miranda, Marcela Martins de Paula Oliveira, Maria Isadora Gabriel Sampaio, João Victor Dutra Gomes, Dâmaris Silveira, Eliete Neves Silva Guerra, Adriana Lofrano‐Porto, Cinthia Gabriel Meireles, Luiz Alberto Simeoni · 2022 · Phytotherapy Research
70. Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer.
    Leandro Salati D'Abronzo, Alan Paul Lombard, Shu Ning, Cameron M Armstong, Amy Rose Leslie, Masuda Sharifi, Zachary A. Schaaf, Wei Lou, Allen C. Gao · 2022 · PubMed Central
71. Phenotypic plasticity and lineage switching in prostate cancer
    Jason A. Somarelli, Andrew J. Armstrong, Maya U. Sheth, Kathryn E. Ware, Mohit Kumar Jolly · 2020 · Elsevier eBooks
72. Characterisation of the long noncoding RNA GHSROS in prostate and breast cancer
    Patrick B. Thomas · 2018 · Queensland University of Technology
73. MicroRNA-194 promotes lineage plasticity in advanced prostate cancer
    Rayzel Candida Fernandes, John Toubia, Scott L. Townley, Adrienne R. Hanson, B. Kate Dredge, Katherine A. Pillman, Andrew G. Bert, Richard D Iggo, Rajdeep Das, Daisuke Obinata et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
74. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapy
    Vipul Bhatia, Nikhil V. Kamat, Tiffany E. Pariva, Liting Wu, Annabelle Tsao, Koichi Sasaki, Lauren Wiest, Ailin Zhang, Dmytro Rudoy, Roman Gulati et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
75. Single-Cell RNAseq Analysis Reveals Robust, Anti-PD-1-Mediated Increase of Immune Infiltrate in Metastatic Castration-Sensitive Prostate Cancer
    Jessica E. Hawley, Aleksandar Obradović, Matthew C. Dallos, Emerson A. Lim, Karie D. Runcie, Casey R. Ager, James McKiernan, Christopher B. Anderson, Joel DeCastro, Joshua L. Weintraub et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
76. Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target
    Marina G. Ferrari, Li Wang, Luke H. Hoeppner, Eunsil Hahm, Jindan Yu, Timothy Michael Kuzel, Adrian Pablo Mansini · 2023 · Research Square
77. Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes
    Anmbreen Jamroze, Xiaozhuo Liu, Surui Hou, Wen Jess Li, Han Yu, Amanda Tracz, Qiuhui Li, Kent L. Nastiuk, Xin Chen, Jiaoti Huang et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
78. SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer
    John T. Phoenix, Audris Budreika, Devin A. Schmeck, Raymond J. Kostlan, Marina G. Ferrari, Kristen S. Young, Charles S. Rogers, Carleen D. Deegan, Marcus W. Bienko, Hannah E. Bergom et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
79. Histopathological and Molecular Markers in the Assessment of Prostate Cancer Aggressivity
    Ljubinka Janković Veličković · 2024 · Springer eBooks
80. Opposing impact of hypertension/diabetes following hormone therapy initiation and preexisting statins on castration resistant progression of nonmetastatic prostate cancer: a multicenter study
    Tomonori Hayashi, Tomoyoshi Miyamoto, Shiori Iwane, Masanori Fujitani, Kazuki Uchitani, Yuichi Koizumi, Atsushi Hirata, Hidefumi Kinoshita, Atsufumi Kawabata · 2024 · Scientific Reports
81. Androgen-ablative therapies inducing CXCL8 regulates mTORC1/SREBP2-dependent cholesterol biosynthesis to support progression of androgen receptor negative prostate cancer cells
    Xingyu Xiong, Shiyu Zhang, Weizhen Zhu, Jiajia Du, Xinyang Liao, Siping Hu, Jie Yang, Weitao Zheng, Shi Qiu, Hang Xu et al. · 2024 · Oncogene
82. MUC1 expression is associated with ST3GAL2 and negatively correlated with the androgen receptor in castration-resistant prostate cancer
    Shotaro Nakanishi, Tetsuji Suda, Kei Tanaka, Tomoko Yonamine, Kenji Numahata, Ai Sugawa, Takuma Oshiro, Yoshinori Oshiro, Seiichi Saito, Junichi Inokuchi · 2024 · Glycoconjugate Journal
83. Prostate luminal cell plasticity and cancer
    Emily C. Williams, Maho Shibata · 2024 · Cancer Letters
84. Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
    Kalpit Shah, Matthew H. Secrest, Wei Zhou, Shu Wang, Dan Canter, Yuxiang Zhang, Dexter X. Jin, Ethan S. Sokol, Małgorzata Nowicka, Armande Ang Houle et al. · 2025 · Clinical Cancer Research
85. The role of LKB1 in prostate cancer: implications for tumor progression and therapy
    Yuwei Liang, Hongliang Cao, Zhijun Tang, Shuxin Li, Gang Yang, Shuai Dong, Hao Du, Jinguo Wang · 2025 · Frontiers in Cell and Developmental Biology
86. Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer
    Galina Semenova, Sander B. Frank, Ruth F. Dumpit, Wanting Han, Ilsa M. Coleman, Roman Gulati, Canan D. Dirican, Tarana Arman, Jessica Maruwan, Colm M. Morrissey et al. · 2026 · Journal of Clinical Investigation
87. Targeting the Androgen Receptor Pathway in Prostate Cancer: A PROTrACted Struggle
    Michael D. Nyquist, Peter S. Nelson · 2025 · Clinical Cancer Research
88. Clofazimine Treatment Modulates Key Non-Coding RNAs Associated with Tumor Progression and Drug Resistance in Lethal Prostate Cancer
    Sarah Batten, Harish Kumar, Jeremiah C. Pfitzer, Daniel Chinedu Nweze, Suman Mazumder, Robert D. Arnold, Panagiotis Mistriotis, Taraswi Mitra Ghosh, Amit Mitra · 2025 · International Journal of Molecular Sciences
89. Multiprobe PET Imaging
    Akshay Sharad Bedmutha, Bruce J. Barron, Stephen K. Lau, Kyle Oi, David C. Brandon · 2025 · Clinical Nuclear Medicine
90. Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohort
    Maximilian Glienke, Ruth Himmelsbach, Max Zirngibl, Patrick Metzger, Julia Kühn, Cornelius Miething, August Sigle, Christian Gratzke, Cathleen Nientiedt, Michael P. Rassner et al. · 2025 · Frontiers in Oncology
91. Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis
    Pusheng Hui, Yanru Lai, Haiqi Fan, Qinrong Yan, Yue Yang, Zhe Chen, Yu Hou, Youlin Kuang · 2025 · Journal of Translational Medicine
92. Integrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancer
    Chennan Li, JuanJuan Yin, Melissa L. Abel, Dana S. Vargas Solivan, Kinjal P. Bhadresha, Sumeyra Kartal, Samantha Nichols, Kanak Parmar, Joseph D. Twohig, Tri M. Truong et al. · 2026 · npj Precision Oncology
93. Fibroblast-mediated KRAS activation in double-negative prostate cancer
    Taiki Kamijima, Kouji Izumi, Kaoru Hiratsuka, Takahiro Inaba, Yoshiki Koketsu, Ryunosuke Nakagawa, Ren Toriumi, Shuhei Aoyama, Hiroshi Kano, Tomoyuki Makino et al. · 2026 · Cell Death and Disease
94. USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer
    Danielle Meiwen Fang, Raj K. Shrestha, Beatriz German, Razia Rahman, Scott L. Townley, Jianling Xie, Adrienne R. Hanson, Richard D Iggo, Zeyad D. Nassar, Madison Helm et al. · 2026 · Cell Death and Disease
95. Double-negative prostate cancer: Evolutionary mechanisms, microenvironmental remodeling, and clinical translation
    Lei Fan, Jiawei Li, Chunhao Mo, Chuanjian Chen, Tianyu Gao, Xuyan Wang, Zhongyun Ning, Ning Fan, Hui Ding · 2026 · Critical Reviews in Oncology/Hematology
96. Castration-Resistant Prostate Cancer: Biological Mechanisms of Therapeutic Escape—On Behalf of the SIU Prostate Cancer Sub-Committee Panel
    Sara Riolo, Giacomo Gallo, Antonio Cicione, Liu Ming, Rodrigo Pessoa, Evan Z. Kovac, R. Krishnappa, Cosimo De Nunzio · 2026 · Société Internationale d’Urologie Journal
97. Discovery proteomics defines androgen-regulated glycoprotein networks in prostate cancer cells, as well as putative biomarkers of prostatic diseases
    Jordy J. Hsiao, Melinda M. Smits, Brandon H. Ng, Jinhee Lee, Michael E. Wright · 2021 · Scientific Reports
98. Xenografts on nude mouse diaphragm of human DU145 prostate carcinoma cells: mesothelium removal by outgrowths and angiogenesis
    Jacques Gilloteaux, James M. Jamison, Jack L. Summers, Henryk S. Taper · 2022 · Ultrastructural Pathology
99. Advances in preclinical models of prostate cancer for research discovery
    Renea A. Taylor, Mitchell G. Lawrence, Gail Petuna Risbridger · 2023 · Journal of Endocrinology
100. Neuroendocrine prostate cancer
     Sufia Safina, Исянгулова Алина Зульфатовна · 2023 · Cancer Urology